Third Harmonic Bio, Inc. is a biopharmaceutical company. The Company is focused on advancing the next wave of medicine for inflammatory diseases through the development of novel, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is developing medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. Mast cells are a part of the immune system, and dysfunctional mast cell activity has been implicated in the pathophysiology of a broad range of inflammatory disorders including urticaria, asthma and gastrointestinal disorders, among others. The Company is advancing its lead product candidate, THB335, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway and gastrointestinal tract. THB335 is a potent, highly selective, oral small molecule KIT inhibitor with a promising preclinical product profile.
Código da empresaTHRD
Nome da EmpresaThird Harmonic Bio Inc
Data de listagemSep 15, 2022
CEO- -
Número de funcionários53
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 15
Endereço1700 Montgomery Street
CidadeSAN FRANCISCO
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal94111
Telefone12097272457
Sitehttps://thirdharmonicbio.com/
Código da empresaTHRD
Data de listagemSep 15, 2022
CEO- -
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados